Here's a number that should make Eli Lilly (LLY) executives extremely nervous: Novo Nordisk A/S (NVO) just moved 20,371 prescriptions of oral Wegovy in its second week on shelves. That's up from 4,289 in week one—a nearly 500% week-over-week explosion that makes every previous GLP-1 launch look pedestrian by comparison.
For perspective, Lilly's Zepbound managed about 10,000 scripts in week two. Novo's original injectable Wegovy? Barely cleared 1,000. This isn't just strong performance. This is a completely different trajectory.
The Numbers Are Probably Even Better Than They Look
The really interesting part is that 20,371 is almost certainly conservative. Here's why: retail script data captures traditional pharmacies like CVS Health Corp (CVS) and Walgreens Boots Alliance, but it completely misses NovoCare, Novo's direct-to-consumer channel where patients can pay $149–$249 out of pocket.
It also excludes telehealth platforms like Hims & Hers Health Inc (HIMS), Ro, and WW International Inc's (WW) WeightWatchers (Sequence), where a growing chunk of GLP-1 prescriptions are being filled these days.
Then there's the insurance bottleneck. Week two patients were still wrestling with prior authorization approvals, creating a backlog of demand that hasn't shown up in the data yet. Put it all together, and real adoption could easily be double or triple what the headline number suggests.
Why Lilly Should Be Worried
Oral GLP-1s fundamentally change the game. Needles kept these drugs niche; pills make them mainstream. And Novo already has distribution locked down in over 70,000 retail locations, building massive brand loyalty well before Lilly's oral contender, Orforglipron, arrives sometime in late 2026.
In pharma, the first-mover advantage is real. Switching patients from one drug to another is hard—getting them to start on your drug in the first place is exponentially easier. Novo just planted its flag first, and that matters enormously.
The Bigger Picture
The GLP-1 market just entered its mass-adoption phase. If oral versions scale the way these early numbers suggest, the total addressable market for weight-loss drugs could expand dramatically—potentially reshaping revenue forecasts for both Novo and Lilly over the next several years.
Wall Street is starting to pay attention, but the velocity here suggests analysts might still be underestimating how quickly the oral GLP-1 era could take off. These aren't just good numbers. They're the kind of numbers that redefine markets.
